Skip to main content
. 2023 May 15;15(5):3489–3499.

Table 4.

CD133 positive Epithelial Circulating Tumor Cells (E-CTC) and baseline characteristics of patients [n (%)]

CD133 positive E-CTC P

≥1 (n=22) <1 (n=41)
Age (years)
    ≥60 16 (72.73) 19 (46.34) 0.045
    <60 6 (27.27) 22 (53.66)
Gender
    Male 14 (63.64) 27 (65.85) 0.860
    Female 8 (36.36) 14 (34.15)
The maximum diameter of the tumor
    ≥5 cm 13 (59.09) 14 (34.15) 0.056
    <5 cm 9 (40.91) 27 (65.85)
TNM stage
    I-II 2 (9.09) 5 (12.20) 0.709
    III-IV 20 (90.91) 36 (87.80)
Degree of differentiation
    High 3 (13.64) 2 (4.88) 0.462
    Intermediate 16 (72.72) 32 (78.05)
    Low 3 (13.64) 7 (17.07)
Lymphatic metastasis
    Yes 18 (81.82) 35 (85.37) 0.713
    No 4 (18.18) 6 (14.63)
Distant metastasis
    Yes 3 (13.64) 14 (34.15) 0.080
    No 19 (83.36) 27 (65.85)
CEA
    <5 ng/mL 18 (81.82) 34 (82.93) 0.912
    ≥5 ng/mL 4 (18.18) 7 (17.07)
CA-199
    <35 U/mL 18 (81.82) 34 (82.93) 0.912
    ≥35 U/mL 4 (18.18) 7 (17.07)

CEA, carcinoembryonic antigen.